07:31 AM EDT, 05/08/2026 (MT Newswires) -- Bristol Myers Squibb (BMY) said Friday that the European Commission approved Sotyktu for adults with active psoriatic arthritis who had an inadequate response or intolerance to prior disease-modifying antirheumatic drug therapy.

Sotyktu is the first and only TYK2 inhibitor approved in the EU for active psoriatic arthritis and can be used alone or with methotrexate, the company said.

The approval was supported by Phase 3 POETYK PsA-1 and PsA-2 trial results showing Sotyktu outperformed placebo at Week 16 across joint and skin symptom measures and quality-of-life endpoints, the company added.